الفهرس 
Classification of diabetes mellitusOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Purpose: The aim of current study is to assess the effect of cabergoline, one of
dopamine agonists on glycemic control, lipid profile, liver functions, dopamine
levels and cardiovascular biomarker, hsCRP on type 2 diabetic patients.
Methods: This prospective randomized parallel study involved fifty diabetic
patients who were divided into two groups. The first group received gliclazide
(60-120 mg) once daily. The second group received cabergoline 0.5 mg twice
weekly plus gliclazide (60-120 mg) once daily. Fasting plasma glucose,
postprandial plasma glucose, glycated haemoglobin (HbA1c), fasting insulin,
Homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile
(total cholesterol, low density lipoproteins (LDL) cholesterol, high density
lipoproteins (HDL) cholesterol, triglycerides), liver function tests
(aspartate transaminase (AST), alanine transaminase (ALT)), dopamine levels,
and high sensitive C-reactive protein were measured at baseline and after 4
months of treatment. Fasting plasma glucose and postprandial plasma glucose
were measured every month.
Results: Treatment of the patients with cabergoline and gliclazide resulted in
greater significant (p<0.05) decrease in FBG, PPBG, HbA1c compared to
treatment with gliclazide only and insignificant (p<0.05) change in ALT and
AST compared to pretreatment normal levels. group 2 diabetic patients exhibit
a significant decrease in (p<0.05) hsCRP compared to pretreatment levels and a
significant increase (p<0.05) in dopamine levels after four months of
cabergoline treatment.
Conclusion: Cabergoline improved glycemic control via resetting
dopaminergic and noradrenergic tone in ventromedial hypothalamus. Insulin
levels were reduced and insulin sensitivity was enhanced with improvement in
lipid profile. Suppression of insulin secretion induces β-cell rest, increases the
number of organ-specific insulin receptors and improves insulin sensitivity.
Cabergoline maintains liver functions (ALT and AST levels) and reduces
hsCRP levels to offer a new promising antidiabetic drug with unique insulin
sensitizing actions and accepted hepatic and cardiovascular safety profile for
type 2 diabetic patients.